John J. Miller, MD

DSM-5-TR is here.

In this CME article, familiarize yourself with various pharmacokinetic, pharmacodynamic, and patient-specific factors to review to develop a successful cross-titration plan from one antipsychotic to another.

Smart phones have the potential to be either a useful and highly constructive asset or a destructive and harmful diversion from life.

Playing with opioids is a dangerous game...

This is the sad reality: In the first year of COVID-19, there were 20,000 more opioid overdose deaths than years previous.

The glass is half full: reflections on where we are and hope for where we are heading in psychiatry.

Here's why the RAISE study is important and what you need to know to help patients.

Is that drug a partial agonist … or a partial agonist?

Collaborative care provides the best possible patient outcomes.

The importance of specifically defining a drug’s mechanism as partial agonism or antagonism/partial agonism for better clinical outcomes.

Thinking about belief systems and preferences that differ from your own? Imagine the human brain as a mansion.

The history of medicine is a never-ending work in progress. What is the next chapter in the psychiatry and genetics story?

The long trail of posttraumatic pain and suffering leaves behind too many people whose lives will never be the same...

10 keys to understanding the science of cannabinoids.

Recognizing the need to stay up-to-date with psychopharmacology and issues affecting psychiatric practice, Psychiatric Times' Editor in Chief invites readers to join him and leaders in psychiatry for a fascinating educational conference.

Early-life stress can modify an individual's genetic code, leading to mental health problems later in life. But by understanding the science of epigenetics, psychiatrists can treat these conditions, and prevent intergenerational trauma.

What treatment options are available when dealing with delirium?

What factors should be considered to help prevent delirium?

Tackling the ABCs of delirium--a challenging diagnosis.

At almost every turn, insurance payers, based on seemingly ignorant and unethical justifications, continue to undermine the quality of psychiatric care.

John J. Miller, MD, formally invites you to the Annual Psychiatric Times® World CME Conference™.

Meditation is a powerful practice with risks and benefits. On rare occasions, those risks can be extreme.

How could drugs that block post-synaptic dopamine 2 receptors increase the risk for tardive dyskinesia over time?

Take the time to focus inward...

The psychiatrist's armamentarium to treat depression holds promise with a growing arsenal of integrative and pharmacologic options.

Meditation is a process and practice available to all.

A message flowing through the brain, across neuronal systems... where is it headed?

Meditation: useful, helpful, and health-promoting for both psychiatrists and patients.

The more tools we have in our treatment toolbox, the greater the likelihood that we will ultimately find a treatment (or combination of treatments) to improve a given patient’s functioning and quality of life.

Taking a closer look at the N-methyl-D-aspartate receptors...